Abstract Maintaining weight is important for better prognosis of breast cancer survivors. The associations between weight and cancer-related symptoms are not known. We examined associations among weight, weight change, inflammation, cancer-related symptoms, and health-related quality of life (HRQOL) in a cohort of stage 0-IIIA breast cancer survivors. Participants were recruited on average 6 months (2-12 months) after diagnosis. Height, weight, and C-reactive protein (CRP) were assessed at approximately 30 months post-diagnosis; cancerrelated symptoms (chest wall and arm symptoms, vasomotor symptoms, urinary incontinence, vaginal symptoms, cognition/mood problems, sleep, sexual interest/function), and HRQOL (SF-36) were assessed at approximately 40 months post-diagnosis. Weight was measured at baseline in a subset. Data on 661 participants were evaluable for body mass index (BMI); 483 were evaluable for weight change. We assessed associations between BMI (\25.0, 25.0-29.9, C30.0 kg/m 2 ), post-diagnosis weight change (lost C5 %, weight change \5 %, gained C5 %), and CRP (tertile) with cancer-related symptoms and HRQOL using analysis of covariance. Higher symptoms scores indicate more frequent or severe symptoms. Higher HRQOL scores indicate better HRQOL. Compared with those with BMI \25 kg/m 2 , women with BMI C30 kg/m 2 had the following scores: increased for arm symptoms (?25.0 %), urinary incontinence (?40.0 %), tendency to nap (?18.9 %), and poorer physical functioning (-15.6 %, all p \ 0.05). Obese women had lower scores in trouble falling asleep (-9.9 %; p \ 0.05). Compared with weight 
Introduction
Cancer-related symptoms such as cognitive problems, pain, insomnia, and urinary incontinence are highly prevalent among breast cancer survivors and can significantly decrease health-related quality of life (HRQOL) [1] [2] [3] [4] . Up to 65 % of breast cancer survivors suffer from persistent pain [3, 5] and menopausal symptoms [6] more than a year after diagnosis.
Maintaining normal weight is associated with improved prognosis in breast cancer survivors [7] ; however, few studies have examined the associations between weight and cancer-related symptoms [8] [9] [10] [11] . In the Health, Eating, Activity and Lifestyle (HEAL) cohort, post-diagnosis weight gain was associated with temporary or sustained changes in sleep patterns [8] , and increase in body mass index [BMI] [5 % from 5-to 10-year follow-up was associated with increased odds of an above-average bodily pain score of the Medical Outcomes Study 36-Item Short Form (SF-36) at 10-year follow-up [10] . A review concluded that obesity is associated with increased risk for cancer-related lymphedema which could cause discomfort and pain in the affected area [11] . In another study of 3,088 breast cancer survivors, those who gained C10 % of prediagnosis weight had an increased risk of hot flashes (odds ratio = 1.33, 95 % CI = 1.11-1.60, vs. maintained weight) [9] . In non-cancer populations, greater weight and adiposity are associated with more severe vasomotor symptoms [12] [13] [14] [15] , and poorer mental health [16, 17] and cognitive function [18, 19] .
Cancer-related symptoms such as fatigue, insomnia, and depression are inter-correlated in breast cancer patients [1, 20, 21] . Cytokines produced in inflammation interfere with both central and peripheral nervous systems that regulate sleep cycle, pain sensation, and cognition [22] . Because of the similarities between cytokine-induced sickness behaviors (e.g., sleepiness and hyperalgesia) [23] and cancer-related symptoms, it is hypothesized that inflammation could be a common biological mechanism [22, 24] . Since obesity is associated with increased levels of inflammatory biomarkers [25] , inflammation may account for the excess symptom burden in obese cancer survivors. Although high levels of circulating inflammatory biomarkers are associated with greater fatigue in breast cancer survivors [20, [26] [27] [28] [29] , we found only one study that examined the associations between inflammatory biomarkers and other breast cancer-related symptoms such as sleep problems and depression [20] . The importance of C-reactive protein (CRP) for cancer survivors was supported by our previous finding of increased mortality with higher CRP levels [30] .
The primary aim of this study was to investigate whether post-diagnosis weight status (BMI), weight change, and the inflammatory biomarker, CRP, were associated with cancer-related symptoms and HRQOL among breast cancer survivors. We hypothesized that high BMI, weight gain, and high levels of CRP would be associated with more severe cancer-related symptoms and worse HRQOL. The secondary aim was to investigate whether BMI and CRP were independently associated with cancer-related symptoms and HRQOL. Understanding these associations could provide important information on potential ways to prevent or alleviate these symptoms in breast cancer survivors.
Patients and methods
Participants and study setting HEAL is a multicenter, multiethnic prospective cohort of 1,183 women diagnosed with first primary stage 0-IIIA breast cancer, designed to examine the effects of weight, physical activity, diet, circulating biomarkers, and other exposures on breast cancer prognosis. Study design, recruitment and eligibility are reported elsewhere [31, 32] . Participants were recruited between 1996 and 1999 within 2-12 months of diagnosis. Study protocols were approved by the Institutional Review Boards of each participating center. All participants provided written informed consent.
Participants completed three assessments: baseline (on average 6 months post-diagnosis), the 30-month (approximately 30 months post-diagnosis) and quality of life (QOL) assessments (approximately 40 months post-diagnosis, Fig. 1 ). Demographic and clinical variables, sleep (average hours/day), and physical activity were assessed at baseline and the 30-month assessments. Weight and height were measured at the baseline and 30-month assessments in New Mexico (NM) and Western Washington (WA), and at the 30-month assessment only in Los Angeles (LA). We collected fasting blood samples at the 30-month assessment. Questionnaires that assessed cancer-related symptoms and HRQOL were completed either at the 30-month assessment (WA), or at the QOL assessment (LA and NM).
A total of 1,183 women completed the baseline assessment; 944 women completed the 30-month assessment; 814 provided a serum sample; and 858 completed the QOL assessment. Women who were diagnosed with a recurrence or a new primary breast cancer during the follow-up were excluded from the analysis. A total of 661 participants with data available on CRP, BMI at 30-month assessment, cancer-related symptoms, and HRQOL were included in the analysis. Data on weight change from baseline to 30-month assessment were available for 483 participants recruited in WA and NM. Compared with participants not included in this analysis (N = 522), those included (N = 661) were on average more likely to be non-Hispanic white, have higher education, with lower tumor stage, and less likely to have had chemotherapy (all p \ 0.01, Online Resource Supplement Table 1 ).
Body measures
Height and weight were measured and BMI was computed as kg/m 2 [25] .
CRP measurement
Fasting blood samples were collected and serum CRP was measured at the University of Washington [25] . The lower Analyzed n = 661 with data on body mass index at the 30-month assessment, C-reactive protein, cancer-related symptoms and health-related quality of life n = 483 with data on weight change from baseline to 30-month assessment, C-reactive protein, cancer-related symptoms and health-related quality of life (New Mexico and Western Washingtononly) detection limit for CRP was 0.2 mg/L. Interassay coefficients of variation were 5-9 %.
Cancer-related symptoms and health-related quality of life measures
Vasomotor symptoms, urinary incontinence, cognitive impairment/mood disturbance, vaginal symptoms, and sleep quality were assessed using a shortened version of the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (BCPT) Hormonal Symptom Checklist [33, 34] . Response for each symptom ranged from 0 (not at all) to 4 (extremely). We calculated the four hormone-related symptom scales: vasomotor, urinary incontinence, cognitive/mood, and vaginal symptoms [34] . Previous analysis of the HEAL cohort have shown good validity and reliability for these scales [34] . Three items from the BCPT Hormonal Symptom Checklist, interrupted sleep, tendency to nap, and trouble getting to sleep, were used to assess sleep problems [33, 34] . We also asked participants to rate their degree of feeling awake in a range of 0 (awake) to 10 (sleepy). Single-item sleep questions have been used in other studies [35] [36] [37] . Hours of sleep on typical weekdays and weekends in the prior year were assessed using the Modifiable Activity Questionnaire [38, 39] .
We assessed chest wall and arm symptoms by asking frequencies of seven physical sensations (i.e., pins and needle sensations, numbness, increased skin sensitivity, swelling, tenderness, tightness, and pain) during the past 3 months [40, 41] . Response ranged from 0 (never) to 4 (very often). These scales were shown to have adequate internal consistency (i.e., Cronbach's alphas = 0.81 for chest wall symptom and 0.88 for arm symptom) in the HEAL cohort [41] .
Sexual function/interest was assessed by the previously validated sexual summary scale from the Cancer Rehabilitation Evaluation System [42] . The score ranged from 0-3; greater scores indicated more problems with sexual function/interest. HRQOL was assessed by the SF-36 [43] . Eight subscales and two summary scores of SF-36 were calculated [43] . The two summary scores were standardized on a T-score metric. All scores ranged from 0-100; higher scores indicated better HRQOL.
Other variables
Standardized questionnaires were used to collect demographic characteristics, medical history, medication use, and smoking habits at baseline and 30-month assessments. A race/study site variable was defined [29] . Tumor stage (in situ, local, and regional) and hormone receptor status (estrogen and progesterone receptors) were obtained from the SEER. Unknown estrogen or progesterone receptor status was coded as 'unknown'. Cancer treatment data were obtained from medical records and SEER. Menopausal status (pre, post, unclassifiable) was determined using an algorithm [34] . Tamoxifen use was self-reported at the 30-month assessment. Women taking medications that have been demonstrated to reduce CRP or other inflammatory biomarkers, including angiotensin I converting enzyme inhibitors, beta-blockers, anti-hyperlipidemics, anti-gout agents, non-steroidal anti-inflammatory drugs, antipyretics, or respiratory corticosteroids, were classified as ''anti-inflammatory medication users'' [44, 45] . Women taking antidepressants, anxiolytics, or sedatives/hypnotics were classified as ''antidepressant/anxiolytic medication users''. A history of medical conditions (i.e., angina/chest pain, heart attack, congestive heart failure, deep venous thrombosis, pulmonary embolism, stroke, arthritis, diabetes/high blood sugar, or other cancer) was self-reported at the 30-month assessment. A number of comorbid conditions were categorized as 0, 1, or C2 [29] . Data regarding type, duration, and frequency of physical activity in the past year were collected at the 30-month assessment [46] . Total average metabolic equivalent task (MET) hours/week (an estimate of energy expenditure based on exercise intensity and duration) of moderate-to-vigorous sport and recreational activities were calculated.
Statistical analysis
Characteristics of participants were compared using the v 2 -, Fisher's exact and t tests, as appropriate. We created subgroups based on BMI (\25.0, 25.0-29.9, C30 kg/m 2 ); weight change since baseline (lost C5 %, maintained [weight change\5 %], and gained C5 %) [47] ; and tertiles of CRP. Linear regression tested the scores and trends (P trend ) of symptoms/HRQOL scores across these subgroups. The symptom/HRQOL scores were compared between these groups using analysis of covariance (ANCOVA). We also tested the associations between weight loss and symptoms/HRQOL (1) stratified by baseline BMI (\25, C25 kg/m 2 ) and (2) including both baseline BMI and weight change as independent variables. The covariates in the models other than BMI and CRP were chosen based on their clinical relevance and significant contributions to the model. The models were further adjusted for BMI or CRP to examine potential confounding effects. A change in b coefficients [10 % was used as a criterion for confounding. We used Cohen's d to assess the clinical significance of the differences between the groups [48] . For HRQOL, score differences of 5-10 points for the eight subscales and 2.5-5 points for the two component summary scores were considered clinically meaningful [48] [49] [50] [51] . We also performed the analyses excluding participants with BMI \18.5 kg/m 2 (N = 8) for the analysis examining associations between BMI and symptoms/ HRQOL (Online Resource Supplement Table 2 ), and CRP outliers (N = 31), defined by the 95th percentile cutoffs from National Health and Nutrition Examination Survey data [52] for the analysis examining associations between CRP and symptoms/HRQOL (Online Resource Supplement Table 3 ). These exclusions did not affect most analysis results except the trends of higher CRP associated with better mental component summary scores became significant (P trend \ 0.05). Therefore, these participants were included in the presented analyses. Although the associations between CRP and vitality scores (HRQOL) were previously reported [29] , we repeated the analysis to confirm the association in breast cancer survivors included in the present analysis. A two-sided alpha of \0.05 was considered statistically significant. All analyses were performed with SAS 9.2 (SAS Institute, Cary, NC, USA).
Results
Of the 661 women, 407 (61.6 %) were non-Hispanic white, 163 (24.7 %) were black, and 70 (10.6 %) were Hispanic ( Table 1 ). The mean (SD) age was 55.5 (10.0) years at baseline. At the 30-month assessment, 76.7 % of the participants were postmenopausal, 45.5 % were taking tamoxifen, and 12 % were current smokers. The mean (SD) BMI was 28.0 (6.3) kg/m 2 and more than 60 % were classified as overweight (BMI = 25-29.9 kg/m 2 ) or obese (BMI C30 kg/m 2 ) at the 30-month assessment. Among our subsample with weight change data available [participants recruited in WA and NM (N = 483)], 45 (9.3 %) lost C5 % weight, 307 (63.6 %) maintained weight, and 131 (27.1 %) gained C5 % weight from baseline to 30-month assessment.
Associations between weight and cancer-related symptoms and health-related quality of life There was a trend for higher BMI to be associated with increasing arm symptom scores: adjusted means for arm symptoms scores were 0. Greater BMI was associated with poor physical functioning (71.0; 66.9; 59.9, respectively, P trend \ 0.0001) and physical component summary scores (42.0; 40.2; 38.5, respectively, P trend \ 0.0001) but with better mental component summary scores (46.7; 47.7; 48.7, respectively, P trend = 0.02). In contrast, survivors with higher BMI had less difficulty falling asleep (2.43; 2.29; 2.19; P trend = 0.02) corresponding to 5.8 and 9.9 % (Cohen's d = 0.16) less problems, respectively, in overweight and obese survivors vs. those with BMI\25 kg/ m 2 . The associations between BMI and symptoms/HRQOL (i.e., urinary incontinence, tendency to nap, difficulty falling asleep, physical functioning, physical and mental component summary scores) were confounded by CRP (Db coefficients [10 %). However, BMI was independently associated with urinary incontinence and physical functioning after adjusting for CRP.
Associations between weight change and cancer-related symptoms and health-related quality of life Chest wall and arm symptoms, physical functioning, rolephysical, and physical component summary scores differed between the subgroups defined by weight change categories (p \ 0.05; Table 3 ). Compared with survivors with weight change \5 %, participants who gained C5 % of baseline weight had lower scores in physical functioning (-7.2 %, -5.5 points), role-physical (-15.5 %, -10.2 points), and physical component summary score (-4.5 %, -1.9 points); weight loss C5 % was associated with less severe chest wall (-33.0 %, Cohen's d = 0.37) and arm (-35.5 %, Cohen's d = 0.09) symptom scores (all p \ 0.05). The associations between weight change with chest wall and arm symptoms and physical functioning scores were independent of CRP.
We also examined associations between weight change and symptoms/HRQOL stratified by baseline BMI (\25, C25 kg/m 2 , Fig. 2 ). Among women with baseline BMI \25 kg/m 2 , weight gain C5 % was associated with lower physical functioning, role-physical, vitality and physical component summary scores (p \ 0.05, vs. weight change \5 %). Among overweight or obese survivors at baseline (BMI C25 kg/m 2 ), weight loss C5 % was associated with less frequent chest wall and arm symptoms, with better mental component summary scores, but with lower physical component summary score (all p \ 0.05, vs. weight change \5 %). When baseline BMI and weight change were simultaneously included in a model, we found that weight loss was associated with less frequent chest wall and arm symptoms, and weight gain was associated with worsened symptoms (Online Resource Supplement Table 4 ). Both weight loss and gain were associated with reduced role-physical scores. Table 1 continued a n = 1 missing for all participants b n = 7 were missing information on 24-month follow-up date c n = 3 missing for all participants and for participants with weight change data All participants (N = 661) Participants with weight change data (N = 483) Being overweight or obese at baseline was associated with more problems with urinary incontinence and tendency to nap, and with poorer physical functioning and bodily pain (vs. BMI\25 kg/m 2 ). Being overweight or obese at baseline as well as weight loss and gain was associated with lower physical component summary scores (p \ 0.05).
Associations between inflammation and cancer-related symptoms and health-related quality of life Increasing CRP tertile was associated with more adverse scores for chest wall symptoms, urinary incontinence, physical functioning, role-physical, vitality and physical component summary score (all P trend \ 0.05, Table 4 ). Survivors in the highest CRP tertile had 18.4 % (Cohen's d = 0.13) greater chest wall symptom scores, 22.4 % (Cohen's d = 0.14) worse urinary incontinence, 13.9 % (10.6 points) lower physical functioning, 14.5 % (9.6 points) lower role-physical, 8.8 % (4.8 points) lower vitality, and 8.3 % (3.6 points) lower physical component summary scores (all p \ 0.05 vs. lowest CRP tertile). The associations of CRP with urinary incontinence, physical functioning, role-physical, vitality, and physical component summary scores were confounded by BMI; however, higher CRP was independently associated with lower physical functioning, role-physical, and physical component summary after adjusting for BMI.
Discussion
In this study, higher BMI and post-diagnosis weight gain were associated with greater degree of cancer-related symptoms including arm and chest wall symptoms, urinary incontinence, and sleep, as well as poorer physical HRQOL. Post-diagnosis weight loss was associated with less chest wall and arm symptoms, while weight gain was associated with poorer HRQOL. The associations between weight change and symptoms/HRQOL differed by baseline BMI (\25 or C25 kg/m 2 ): weight gain C5 % was associated with lower HRQOL only among women with baseline BMI\25 kg/m 2 , while weight loss C5 % was associated with less severe chest wall and arm symptoms and with better mental HRQOL among survivors with baseline BMI C25 kg/m 2 . Increased CRP was associated with greater chest wall symptom, more difficulty with bladder control, and worse physical functioning, role-physical and vitality scores.
Arm and chest wall symptoms such as pain are common even years after completion of breast cancer treatments [3, [53] [54] [55] and can be caused by multiple pathologic mechanisms [3] . Our study suggests that elevated CRP is one potential mechanism. We also found a trend that higher BMI was associated with greater arm symptoms, while weight loss C5 % was associated with less arm and chest wall symptoms (vs. no weight change). The associations between weight change and arm and chest wall symptoms persisted after adjustment for CRP suggesting an independent association of weight with these symptoms.
Consistent with findings in a non-cancer population [56] , higher BMI was associated with more difficulties with bladder control in breast cancer survivors. We also found a positive association between CRP and urinary incontinence. The association became non-significant after adjusting for BMI, suggesting that BMI confounded the associations between inflammation and urinary problems or that BMI and CRP share a causal pathway. High levels of CRP among obese women may affect urinary incontinence through increased inflammatory reactions such as oxidative stress and vascular damage which could cause pelvic and bladder muscular damage [57] .
Higher BMI was associated with greater tendency to nap but with less trouble getting to sleep among breast cancer survivors. A review reported that obese individuals are more likely than normal-weight persons to suffer from daytime sleepiness [58] . Weight loss through dietary change and surgery has been shown to improve obstructive sleep apnea [59] and daytime hypersomnolence [60] in obese patients. A longitudinal analysis of the Nurse's Health Study found positive associations between short sleep duration and future weight gain and obesity [61] . The associations between body weight and sleep, therefore, could be bi-directional. In addition, studies have shown that sleep is affected by various factors including cancer treatment [8] , fatigue [21] , and menopausal symptoms [6] in breast cancer survivors. Future studies are needed to assess the associations between body weight and different aspects of sleep in this population.
Consistent with previous reports of breast and endometrial cancer survivors [62, 63] , high BMI and weight gain were associated with lower physical aspects of HRQOL in our study. Furthermore, CRP was inversely associated with physical functioning, role-physical, and physical component summary scores, independent of body weight. A recent study in 250 healthy older adults showed that interleukin-6 (an inflammatory biomarker) was inversely associated with physical functioning (HRQOL) adjusting for age, gender, BMI, and health conditions [64] . Systemic inflammation is associated with increased risk of cardiovascular disease [65] , type 2 diabetes [66] , metabolic syndrome [66] , cognitive disorders [67] and depression [68] which could have detrimental effects on both physical and mental HRQOL. In addition, in the HEAL cohort, CRP is higher with African-American ethnicity, increased age, presence of co-morbid conditions, current smoking and lower with higher physical activity and tamoxifen use [25] . Although we adjusted for these variables, it is possible that other factors such as self-report bias, severity of medical conditions, and other medical conditions affecting both CRP and HRQOL could account for the observed association between CRP and physical HRQOL. More studies are needed to determine pathological mechanisms of how CRP affects HRQOL and effects of various medical conditions on these relationships.
Strengths of this study include a large, multiethnic sample of breast cancer survivors, longitudinal data on weight, availability of anthropometric and biomarker measures, and use of validated measures to assess cancerrelated symptoms and HRQOL. There were several limitations. Height, weight, and blood samples were collected prior to assessment of cancer-related symptoms and HRQOL. Changes in weight and CRP between these assessments could have affected cancer-related symptoms and HRQOL. However, we believe that the time between CRP and symptoms/HRQOL assessments did not have large effects on the observed associations. For example, the Pearson's correlation coefficient between the baseline and 12-month CRP levels in 187 middle-aged and postmenopausal women (i.e., the control group of previously completed diet and exercise trials) was 0.81 (p \ 0.001). Similarly, studies have shown that CRP is a stable biomarker over 1 year [69, 70] . The participants included in this analysis were more likely to be non-Hispanic white, have higher education, with lower tumor stage, and less likely to have had chemotherapy compared with those who were not included, limiting the generalizability of our findings. Also, our weight change analysis was limited to Hispanic and non-Hispanic white women. Finally, the observed associations between weight, CRP, and cancerrelated symptoms do not imply causality. Randomized controlled trials are needed to test effects of weight loss and reduced CRP on these symptoms.
In conclusion, BMI and CRP were associated with several breast cancer-related symptoms. Although the observed associations between weight, CRP, and symptoms/HRQOL require further investigation, our findings suggest that interventions to maintain healthy weight and to reduce inflammation could potentially alleviate cancerrelated symptoms and improve HRQOL of breast cancer survivors. Given the high prevalence of obesity and postdiagnosis weight gain [71, 72] and their associations with poor prognosis among breast cancer survivors [7] , our findings underscore the importance of weight control in this population.
